145 related articles for article (PubMed ID: 26688535)
1. Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan.
Watanabe A; Matsumoto T; Igari H; Sawa J; Yamaguchi Y; Sakatani M
Int J Tuberc Lung Dis; 2016 Jan; 20(1):101-8. PubMed ID: 26688535
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy.
Chen DY; Shen GH; Hsieh TY; Hsieh CW; Lan JL
Arthritis Rheum; 2008 Jun; 59(6):800-6. PubMed ID: 18512714
[TBL] [Abstract][Full Text] [Related]
3. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
[TBL] [Abstract][Full Text] [Related]
4. [Biologics and mycobacterial diseases].
Tsuyuguchi K; Matsumoto T
Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
[TBL] [Abstract][Full Text] [Related]
5. Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden.
Shin A; Lee YJ; Lee EB; Song YW; Kim SC; Kang EH
Rheumatology (Oxford); 2021 Jun; 60(6):2755-2764. PubMed ID: 33188421
[TBL] [Abstract][Full Text] [Related]
6. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
Arkema EV; Jonsson J; Baecklund E; Bruchfeld J; Feltelius N; Askling J;
Ann Rheum Dis; 2015 Jun; 74(6):1212-7. PubMed ID: 24608401
[TBL] [Abstract][Full Text] [Related]
7. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients.
Harigai M; Tsuchiya T; Kawana K; Kurimoto S
Mod Rheumatol; 2018 Jan; 28(1):30-38. PubMed ID: 28388293
[TBL] [Abstract][Full Text] [Related]
9. Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan.
Yamanaka H; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Tanaka Y; Suzuki H; Shinmura Y; Koike T
Mod Rheumatol; 2015 Jul; 25(4):495-502. PubMed ID: 25487291
[TBL] [Abstract][Full Text] [Related]
10. The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature.
Scrivo R; Sauzullo I; Mengoni F; Riccieri V; Altieri AM; Cantoro L; Vullo V; Mastroianni CM; Valesini G
Clin Rheumatol; 2016 May; 35(5):1383-8. PubMed ID: 24827875
[TBL] [Abstract][Full Text] [Related]
11. Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.
Liao TL; Lin CH; Chen YM; Chang CL; Chen HH; Chen DY
PLoS One; 2016; 11(4):e0153217. PubMed ID: 27064275
[TBL] [Abstract][Full Text] [Related]
12. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan.
Lim CH; Chen HH; Chen YH; Chen DY; Huang WN; Tsai JJ; Hsieh TY; Hsieh CW; Hung WT; Lin CT; Lai KL; Tang KT; Tseng CW; Chen YM
PLoS One; 2017; 12(6):e0178035. PubMed ID: 28570568
[TBL] [Abstract][Full Text] [Related]
13. [ANTI-TUBERCULOSIS THERAPY AND PARADOXICAL RESPONSE WHEN TUBERCULOSIS DEVELOPS UNDER THE INFLUENCE OF BIOLOGICS FOR RHEUMATOID ARTHRITIS].
Matsumoto T
Kekkaku; 2015; 90(11-12):707-13. PubMed ID: 26979042
[TBL] [Abstract][Full Text] [Related]
14. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.
Boqaeid A; Layqah L; Alonazy A; Althobaiti M; Almahlawi AZ; Al-Roqy A; Baharoon O; Alsaeedi A; Shamou J; Baharoon S
J Infect Public Health; 2024 Jun; 17(6):1134-1141. PubMed ID: 38728834
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
[TBL] [Abstract][Full Text] [Related]
17. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.
Schiff MH; Burmester GR; Kent JD; Pangan AL; Kupper H; Fitzpatrick SB; Donovan C
Ann Rheum Dis; 2006 Jul; 65(7):889-94. PubMed ID: 16439435
[TBL] [Abstract][Full Text] [Related]
18. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
19. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
[TBL] [Abstract][Full Text] [Related]
20. Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease.
Ogata H; Watanabe M; Matsui T; Hase H; Okayasu M; Tsuchiya T; Shinmura Y; Hibi T
J Crohns Colitis; 2016 Sep; 10(9):1033-41. PubMed ID: 26961546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
